References and Included Studies

1. Innis S. Essential dietary lipids. In: Present knowledge in nutrition. Washington, DC: International Life Sciences Institute; 1996.

2. James M, Gibson R, Cleland L. Dietary polyunsaturated fatty acids and inflammatory mediator production. *American Journal of Clinical Nutrition* 2000;71(1):343S-348S.

3. Fallon S, Enig MG. The Price-Pottenger Nutrition Foundation. Tripping Lightly Down the Prostaglandin Pathways. *http://www.price-pottenger.org/Articles/Prostaglandin.htm* 2001.

4. Simopoulos A. The importance of the ratio of omega-6/omega-3 essential fatty acids. *Biomedicine & Pharmacotherapy* 2002;56(8):365-379.

5. Institute of Medicine. . Dietary Reference Intakes: Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrition). The National Academies Press. 2002 (Abstract)

6. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA* 1995;273(5):408-12.

7. Ioannidis JP, Cappelleri JC, Lau J et al. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness. *Ann Intern Med* 1995;122(11):856-866.

8. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for Meta-Analysis in Medical Research. In: Wiley Series in Probability and Statistics. Chichester, UK: John Wiley & Sons; 2000.

9. Hedges LV, Olkin L. Statistical Methods for Meta-Analysis. San Diego, CA: Academic Press, Inc; 1985.

10. Rosenthal R. Meta-Analytic Procedures for Social Research. In: Applied Social Research Methods Series. Newbury Park: Sage Publications; 1991.

11. DerSimonian R., Laird N. Meta-analysis in clinical trials. *Control Clin rials* 1986;7(3):177-188.

12. Egger M, Davey Smith G, Schneider M/ Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997; 315(7109):629-634.

13. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publiction bias. *Biometrics* 1994;50(4):1088-1101.

14. .Stata Statistical Software: Release 7.0 [computer program]. Version 7.0. 2001.

15. Joint Task Group (CHPA, CRN, NFI). Food Labeling: Health Claims and Label Statement - Omega-3 Fatty Acids and Coronary Heart Disease . *Docket No: 91N-0103* .

16. Cleland L, French J, Betts W, Murphy G, Elliott M. Clinical and biochemical effects of dietary fish oil supplements in rheumatoid arthritis. *Journal of Rheumatology* 1988;15(10):1471-1475.

17. Geusens P, Wouters C, Nijs J, Jiang Y, Dequeker J. Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis: A 12-month, double-blind, controlled study. *Arthritis & Rheumatism* 1994 ;37(6):824-829.

18. Kremer J, Bigauoette J, Michaler A. Effects of manipulations of dietary fatty acids on clinical manifestations of rheumatoid arthritis. *Lancet* 1985;1(8422):184-187.

19. Kremer J, Lawrence D, Jubiz W, DiGiacomo R, Rynes R, Bartholomew L, et al. Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. *Arthritis & Rheumatism* 1990;33(6):810-820.

20. Magalish T, Ivanov E, Iubitskaia N. Ultraphonophoresis of omega-3 polyunsaturated fatty acids in the complex therapy of rheumatoid arthritis. *Voprosy.Kurortologii., Fizioterapii.i.Lechebnoi.Fizicheskoi.Kultury* 2002 ;(2):43-44.

21. Magaro M, Altomonte L, Zoli A, Mirone L, De Sole P, Di Mario G, et al. Influence of diet with different lipid composition on neutrophil chemiluminescence and disease activity in patients with rheumatoid arthritis. *Annals of the Rheumatic Diseases* 1988;47(10):793-796.

22. Nielsen G, Faarvang K, Thomsen B, Teglbjaerg K, Jensen L, Hansen T, et al. The effects of dietary supplementation with n-3 polyunsaturated fatty acids in patients with rheumatoid arthritis: a randomized, double blind trial. *European Journal of Clinical Investigation* 1992;22(10):687-691.

23. Nordstrom D, Honkanen V, Nasu Y, Antila E, Friman C, Konttinen Y. Alpha-linolenic acid in the treatment of rheumatoid arthritis: A double blind, placebo-controlled and randomized study: Flaxseed vs safflower seed. *Rheumatology International* 1995;14(6):231-234.

24. Tulleken J, Limburg P, Muskiet F, van Rijswijk M. Vitamin E status during dietary fish oil supplementation in rheumatoid arthritis. *Arthritis & Rheumatism* 1990;33(9):1416-1419.

25. Skoldstam L, Borjesson O, Kjallman A, Seiving B, Akesson B. Effect of six months of fish oil supplementation in stable rheumatoid arthritis. A double blind, controlled study. *Scand J Rheumatol* 1992;21:178-85.

26. Adam O, Beringer C, Kless T, Lemmen C, Adam A, Wiseman M, et al. Anti-inflammatory effects of a low arachidonic acid diet and fish oil in patients with rheumatoid arthritis. *Rheumatology International* 2003;23(1):27-36.

27. Alpigiani M, Ravera G, Buzzanca C, Devescovi R, Fiore P, Iester A. Use of n-3 fatty acids in Juvenile Chronic Arthritis (JCA). *Pediatria Medica e Chirurgica* 1996;18(4):387-390.

28. Belch J, Ansell D, Madhok R, O'Dowd A, Sturrock R. Effects of altering dietary essential fatty acids on requirements for non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis: A double blind placebo controlled study. *Annals of the Rheumatic Diseases* 1988;47(2):96-104.

29. Hansen G, Nielsen L, Kluger E, Thysen M, Emmertsen H, Stengaard-Pedersen K, et al. Nutritional status of Danish rheumatoid arthritis patients and effects of a diet adjusted in energy intake, fish-meal, and antioxidants. *Scandinavian Journal of Rheumatology* 1996;25(5):325-330.

30. Kjeldsen-Kragh J, Lund J, Riise T, Finnanger B, Haaland K, Finstad R, et al. Dietary omega-3 fatty acid supplementation and naproxen treatment in patients with rheumatoid arthritis. *Journal of Rheumatology* 1992;19(10):1531-1536.

31. Kremer J, Lawrence D, Petrillo G, Litts L, Mullaly P, Rynes R, et al. Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs: Clinical and immune correlates. *Arthritis & Rheumatism* 1995;38(8):1107-1114.

32. Lau C, Morley K, Belch J. Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis--a double-blind placebo controlled study. *British Journal of Rheumatology* 1993;32(11):982-989.

33. van der Tempel H, Tulleken J, Limburg P, Muskiet F, van Rijswijk M. Effects of fish oil supplementation in rheumatoid arthritis. *Annals of the Rheumatic Diseases* 1990;49(2):76-80.

34. Tulleken J, Limburg P, van Rijswijk M. Fish oil and plasma fibrinogen. *BMJ* 1988;297:615-616.

35. Volker D, Fitzgerald P, Major G, Garg M. Efficacy of Fish Oil Concentrate in the Treatment of Rheumatoid Arthritis. *J Rheumatol* 2000;27:2343-6.

36. Astorga G. Active rheumatoid arthritis: effect of dietary supplementation with omega-3 oils. A controlled double-blind trial. *Revista Medica de Chile* 1991;119(3):267-272.

37. Espersen G, Grunnet N, Lervang H, Nielsen G, Thomsen B, Faarvang K, et al. Decreased interleukin-1 beta levels in plasma from rheumatoid arthritis patients after dietary supplementation with n-3 polyunsaturated fatty acids. *Clinical Rheumatology* 1992;11(3):393-395.

38. Lau C, McLaren M, Belch J. Effects of fish oil on plasma fibrinolysis in patients with mild rheumatoid arthritis. *Clinical & Experimental Rheumatology* 1995;13(1):87-90.

39. Loeschke K, Ueberschaer B, Pietsch A, Gruber E, Ewe K, Wiebecke B, et al. n-3 fatty acids only delay early relapse of ulcerative colitis in remission. *Digestive Diseases & Sciences* 1996;41(10):2087-2094.

40. Mantzaris G, Archavlis E, Zografos C, Petraki K, Spiliades C, Triantafyllou G. A prospective, randomized, placebo-controlled study of fish oil in ulcerative colitis. *Hellenic Journal of Gastroenterology* 1996;9(2):138-141.

41. Hawthorne A, Daneshmend T, Hawkey C, Shaheen M, Edwards T, Filipowicz B, et al. Fish oil in ulcerative colitis: Final results of a controlled cliinical trial. *Gastroenterology* 98:A174.

42. Greenfield S , Green A, Teare J, Jenkins A, Punchard N, Ainley C, et al. A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis. *Alimentary Pharmacology & Therapeutics* 1993;7(2):159-166.

43. Middleton S, Naylor S, Woolner J, Hunter J. A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. *Alimentary Pharmacology & Therapeutics* 2002;16(6):1131-1135.

44. Almallah Y, Richardson S, O'Hanrahan T, Mowat N, Brunt P, Sinclair T, et al. Distal procto-colitis, natural cytotoxicity, and essential fatty acids. *American Journal of Gastroenterology* 1998;93(5):804-809.

45. Almallah Y, Ewen S, El Tahir A, Mowat N, Brunt P, Sinclair T , et al. Distal proctocolitis and n-3 polyunsaturated fatty acids (n-3 PUFAs): the mucosal effect in situ. *Journal of Clinical Immunology* 2000;20(1):68-76.

46. Aslan A, Triadafilopoulos G. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. *American Journal of Gastroenterology* 1992;87(4):432-437.

47. Belluzzi A, Brignola C, Campieri M, Camporesi E, Gionchetti P, Rizzaello F, et al. Effects of a new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients. *Dig Dis Sci* 1994;39:2589-2594.

48. Dichi I, Frenhane P, Dichi J, Correa C, Angeleli A, Bicudo M, et al. Comparison of omega-3 fatty acids and sulfasalazine in ulcerative colitis. *Nutrition* 2000;16(2):87-90.

49. Hillier K. Human colon mucosa: effect of marine oils on lipid fatty acid composition and eicosanoid synthesis in inflammatory bowel disease. *British Journal of Clinical Pharmacology* 1988;25(1):129P-30P.

50. Hillier K, Jewell R, Dorrell L, Smith C. Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. *Gut* 1991;32(10):1151-1155.

51. Ikehata A, Hiwatashi N, Kinouchi Y, Yamazaki H, Kumagai Y, Ito K, et al. Effect of intravenously infused eicosapentaenoic acid on the leukotriene generation in patients with active Crohn's disease. *American Journal of Clinical Nutrition* 1992;56(5):938-942.

52. Lorenz R, Weber P, Szimnau P, Heldwein W, Strasser T, Loeschke K. Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease--a randomized, placebo-controlled, double-blind cross-over trial. *Journal of Internal Medicine Supplement* 1989;225(731):225-232.

53. Stenson W, Cort D, Rodgers J, Burakoff R, DeSchryver-Kecskemeti K, Gramlich T, et al. Dietary supplementation with fish oil in ulcerative colitis. *Annals of Internal Medicine* 1992;116(8):609-614.

54. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. *New England Journal of Medicine* 1996;334(24):1557-1560.

55. Lorenz-Meyer H, Bauer P, Nicolay C, Schulz B, Purrmann J, Fleig W, et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group). *Scandinavian Journal of Gastroenterology* 1996;31(8):778-785.

56. Shimizu H, Ohtani K, Tanaka Y, Sato N, Mori M, Shimomura Y. Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients. *Diabetes Research & Clinical Practice* 1995;28(1):35-40.

57. Annuzzi G, Rivellese A, Capaldo B, Di Marino L, Iovine C, Marotta G, et al. A controlled study on the effects of n-3 fatty acids on lipid and glucose metabolism in non-insulin-dependent diabetic patients. *Atherosclerosis* 1991;87(1):65-73.

58. Chan D, Watts G, Mori T, Barrett P, Beilin L, Redgrave T. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. *European Journal of Clinical Investigation* 2002;32(6):429-436.

59. Dunstan D, Mori T, Puddey I, Beilin L, Burke V, Morton A, et al. Exercise and fish intake: Effects on serum lipids and glycemic control for type 2 diabetics. *Cardiology Review* 1998;15(8):34-37.

60. Hendra T, Britton M, Roper D, Wagaine-Twabwe D, Jeremy J, Dandona P, et al. Effects of fish oil supplements in NIDDM subjects. Controlled study. *Diabetes Care* 1990;13(8):821-829.

61. Morgan W, Raskin P, Rosenstock J. A comparison of fish oil or corn oil supplements in hyperlipidemic subjects with NIDDM. *Diabetes Care* 1995;18(1):83-86.

62. Pelikanova T , Kohout M, Valek J, Kazdova L, Base J. Metabolic effects of omega-3 fatty acids in type 2 (non-insulin-dependent) diabetic patients. *Annals of the New York Academy of Sciences* 1993;683:272-278.

63. Petersen M, Pedersen H, Major-Pedersen A, Jensen T, Marckmann P. Effect of fish oil versus corn oil supplementation on LDL and HDL subclasses in type 2 diabetic patients. *Diabetes Care* 2002;25(10): 1704-1708.

64. Sirtori C, Crepaldi G, Manzato E, Mancini M, Rivellese A, Paoletti R, et al. One-year treatment with ethyl esters of n-3 fatty acids in patients with hypertriglyceridemia and glucose intolerance: reduced triglyceridemia, total cholesterol and increased HDL-C without glycemic alterations. *Atherosclerosis* 1998;137(2):419-427.

65. Alekseeva R, Sharafetdinov K, Kh Plotnikova OA, Meshcheriakova V, Mal'tsev G, Kulakova S. Effects of a diet including linseed oil on clinical and metabolic parameters in patients with type 2 diabetes mellitus. *Voprosy Pitaniia* 2000;69(6):32-35.

66. Meshcheriakova V, Plotnikova O, Sharafetdinov K, Kh AR, Mal'tsev G, Kulakova S. Comparative study of effects of diet therapy including eiconol or linseed oil on several parameters of lipid metabolism in patients with type 2 diabetes mellitus . *Voprosy Pitaniia* 2001;70(2):28-31.

67. Morgan WA. The effects of fish oil versus corn oil on subjects with hyperlipidemia and type ii, noninsulin-dependent diabetes mellitus (Fatty acids). *Dissertation Abstracts International* 51-06, Section: B:2825-.

68. Patti L, Maffettone A, Iovine C, Marino L, Annuzzi G, Riccardi G, et al. Long-term effects of fish oil on lipoprotein subfractions and low density lipoprotein size in non-insulin-dependent diabetic patients with hypertriglyceridemia. *Atherosclerosis* 1999;146(2):361-367.

69. Rivellese A, Maffettone A, Iovine C, Di Marino L, Annuzzi G, Mancini M, et al. Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia. *Diabetes Care* 1996 ;19(11):1207-1213.

70. Sarkkinen E, Schwab U, Niskanen L, Hannuksela M, Savolainen M, Kervinen K, et al. The effects of monounsaturated-fat enriched diet and polyunsaturated-fat enriched diet on lipid and glucose metabolism in subjects with impaired glucose tolerance. *European Journal of Clinical Nutrition* 1996;50(9):592-598.

71. Westerveld H , de Graaf J, van Breugel H, Akkerman J, Sixma J, Erkelens D, et al. Effects of low-dose EPA-E on glycemic control, lipid profile, lipoprotein(a), platelet aggregation, viscosity, and platelet and vessel wall interaction in NIDDM. *Diabetes Care* 1993;16(5):683-688.

72. Woodman R, Mori T, Burke V, Puddey I, Watts G, Beilin L. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. *American Journal of Clinical Nutrition* 2002;76(5):1007-1015.

73. Maffettone A. Long-term effects (six months) of omega-3 polyunsaturated fatty acids on insulin sensitivity and lipid metabolism in patients with type 2 diabetes and hypertriglycaeridemia. *Giornale Italiano di Diabetologia* 1996;16(4):185-193.

74. Hermans M, Sauvegarde A, Ketelslegers J, Lambert A. Effects of omega-3 fatty acids on insulin-dependent diabetic patients with microalbuminuria. *European Journal of Clinical Investigation* 23(Suppl 1).

75. Axelrod L, Camuso J, Williams E, Kleinman K, Briones E, Schoenfeld D. Effects of a small quantity of omega-3 fatty acids on cardiovascular risk factors in NIDDM. A randomized, prospective, double-blind, controlled study. *Diabetes Care* 1994;17(1):37-44.

76. Boberg M, Pollare T, Siegbahn A, Vessby B. Supplementation with n-3 fatty acids reduces triglycerides but increases PAI-1 in non-insulin-dependent diabetes mellitus. *European Journal of Clinical Investigation* 1992;22(10):645-650.

77. Borkman M, Chisholm D, Furler S, Storlien L, Kraegen E, Simons L, et al. Effects of fish oil supplementation on glucose and lipid metabolism in NIDDM. *Diabetes* 1989;38(10):1314-1319.

78. Connor W, Prince M, Ullmann D, Riddle M, Hatcher L, Smith F, et al. The hypotriglyceridemic effect of fish oil in adult-onset diabetes without adverse glucose control. *Annals of the New York Academy of Sciences* 1993;683:337-340.

79. Fasching P, Rohac M, Liener K, Schneider B, Nowotny P, Waldhausl W. Fish oil supplementation versus gemfibrozil treatment in hyperlipidemic NIDDM. A randomized crossover study. *Hormone & Metabolic Research* 1996;28(5):230-236.

80. Goh Y, Jumpsen J, Ryan E, Clandinin M. Effect of omega 3 fatty acid on plasma lipids, cholesterol and lipoprotein fatty acid content in NIDDM patients. *Diabetologia* 1997;40(1):45-52.

81. Jensen T, Stender S, Goldstein K, Holmer G, Deckert T. Partial normalization by dietary cod-liver oil of increased microvascular albumin leakage in patients with insulin-dependent diabetes and albuminuria. *New England Journal of Medicine* 1989;321(23):1572-1577.

82. Luo J, Rizkalla S, Vidal H, Oppert J, Colas C, Boussairi A, et al. Moderate intake of n-3 fatty acids for 2 months has no detrimental effect on glucose metabolism and could ameliorate the lipid profile in type 2 diabetic men. Results of a controlled study. *Diabetes Care* 1998;21(5):717-724.

83. McGrath L, Brennan G, Donnelly J, Johnston G, Hayes J, McVeigh G. Effect of dietary fish oil supplementation on peroxidation of serum lipids in patients with non-insulin dependent diabetes mellitus. *Atherosclerosis* 1996;121(2):275-283.

84. McVeigh G, Brennan G, Johnston G, McDermott B, McGrath L, Henry W, et al. Dietary fish oil augments nitric oxide production or release in patients with type 2 (non-insulin-dependent) diabetes mellitus. *Diabetologia* 1993;36(1):33-38.

85. McVeigh G, Brennan G, Cohn J, Finkelstein S, Hayes R, Johnston G. Fish oil improves arterial compliance in non-insulin-dependent diabetes mellitus. *Arteriosclerosis & Thrombosis* 1994;14(9):1425-1429.

86. Puhakainen I , Ahola I, Yki-Jarvinen H. Dietary supplementation with n-3 fatty acids increases gluconeogenesis from glycerol but not hepatic glucose production in patients with non-insulin-dependent diabetes mellitus. *American Journal of Clinical Nutrition* 1995;61(1):121-126.

87. Schectman G, Kaul S, Kissebah A. Effect of fish oil concentrate on lipoprotein composition in NIDDM. *Diabetes* 1988;37(11):1567-1573.

88. Schwab U, Sarkkinen E, Lichtenstein A, Li Z, Ordovas J, Schaefer E, et al. The effect of quality and amount of dietary fat on the susceptibility of low density lipoprotein to oxidation in subjects with impaired glucose tolerance. *European Journal of Clinical Nutrition* 1998;52(6):452-458.

89. Sirtori C, Paoletti R, Mancini M, Crepaldi G, Manzato E, Rivellese A, et al. N-3 fatty acids do not lead to an increased diabetic risk in patients with hyperlipidemia and abnormal glucose tolerance. Italian Fish Oil Multicenter Study. *American Journal of Clinical Nutrition* 1997;65(6):1874-1881.

90. Vandongen R, Mori T, Codde J, Stanton K, Masarei J. Hypercholesterolaemic effect of fish oil in insulin-dependent diabetic patients. *Medical Journal of Australia* 1988;148(3):141-143.

91. Vessby B, Boberg M. Dietary supplementation with n-3 fatty acids may impair glucose homeostasis in patients with non-insulin-dependent diabetes mellitus. *Journal of Internal Medicine* 1990;228(2):165-171.

92. Chan D, Watts G, Barrett P, Beilin L, Redgrave T, Mori T. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. *Diabetes* 2002;51(8):2377-2386.

93. Dunstan D, Mori T, Puddey I, Beilin L, Burke V, Morton A, et al. The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in NIDDM. A randomized controlled study. *Diabetes Care* 1997;20(6):913-921.

94. Varghese T, Coomansingh D. Clinical response of ulcerative colitis with dietary omega-3 fatty acids: a double-blind randomized study. *British Journal of Surgery* 2000;87(1):73.

95. Hawthorne A, Daneshmend T, Hawkey C, Belluzzi A, Everitt S, Holmes G, et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. *Gut* 1992;33(7):922-928.

96. Sperling R, Weinblatt M, Robiin J, Ravalese J, Hoover R, House Fea. Effects of dietary supplementation with marine fish oil on leukoeyte lipid mediators and function in rheumatoid rthritis. *Arthritis Rheum* 1987;30:988-997.

97. Fortin P, Lew R, Liang M, Wright E, Beckett L, Chalmers T, et al. Validation of a meta-analysis: The effects of fish oil in rheumatoid arthritis. *Journal of Clinical Epidemiology* 1995;48(11):1379-1390.

98. Donadio J, Jr, Bergstralh E, Offord K, Spencer D, Holley K. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. *New England Journal of Medicine* 1994;331(18):1194-1199.

99. Clark W, Parbtani A, Naylor C, Levinton C, Muirhead N, Spanner E, et al. Fish oil in lupus nephritis: clinical findings and methodological implications. *Kidney International.* 1993;44(1):75-86.

100. Bennett W, Walker R, Kincaid-Smith P. Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two-year prospective trial. *Clinical Nephrology* 1989;31(3):128-131.

101. Pettersson E, Rekola S, Berglund L, Sundqvist K, Angelin B, Diczfalusy U, et al. Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study. *Clinical Nephrology* 1994;41(4):183-190.

102. Schmitz P, McCloud L, Reikes S, Leonard C, Gellens M. Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. *Journal of the American Society of Nephrology* 2002 ;13(1):184-190.

103. de Fijter C , Popp-Snijders C, Oe L, Tran D, van der M, Donker A. Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients? *Haematologica* 1995;80(4):332-334.

104. Donadio J, Jr, Larson T, Bergstralh E, Grande J. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. *Journal of the American Society of Nephrology* 2001;12(4):791-799.

105. Dillon JJ. Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. *Journal of the American Society of Nephrology* 1997;8(11):1739-1744.

106. Gentile M, Fellin G, Cofano F, Delle Fave A, Manna G, Ciceri R, et al. Treatment of proteinuric patients with a vegetarian soy diet and fish oil. *Clinical Nephrology* 1993;40(6):315-320.

107. Walton A, Snaith M, Locniskar M, Cumberland A, Morrow W, Isenberg D. Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus. *Annals of the Rheumatic Diseases.* 1991;50(7):463-466.

108. Westberg G, Tarkowski A. Effect of MaxEPA in patients with SLE. A double-blind, crossover study. *Scandinavian Journal of Rheumatology.* 1990;19(2):137-143.

109. Bassey E, Littlewood J, Rothwell M, Pye D. Lack of effect of supplementation with essential fatty acids on bone mineral density in healthy pre- and postmenopausal women: two randomized controlled trials of Efacal v. calcium alone. *British Journal of Nutrition* 2000;83(6):629-635.

110. Kruger M, Coetzer H, de Winter R, Gericke G, van Papendorp D. Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis. *Aging (Milano).* 1998;10(5):385-394.

111. Terano T. Effect of omega 3 polyunsaturated fatty acid ingestion on bone metabolism and osteoporosis. *World Review of Nutrition & Dietetics* 2001;88:141-147.

112. Tsuchida K, Mizushima S, Toba M, Soda K. Dietary soybeans intake and bone mineral density among 995 middle-aged women in Yokohama. *Journal of Epidemiology.* 1999;9(1):14-19.

113. Jadad A, Moore A, Carrol D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17:1-12.

114. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? LANCET. 1998;352: 609-613.

115. Khan KS, Daya S, Jadad AR. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med. 1996;156:661-666.

116. Montori VM, Farmer A, Wollan PC, Dinneen SF. Fish oil supplementation in type 2 diabetes: a quantitative systematic review. *Diabetes Care.* 2000;23(9): 1407-1415.

117. Cheng IK, Chan PC, Chan MK. The effect of fish-oil dietary supplement on the progression of mesangial IgA glomerulonephritis. *Nephrology Dialysis Transplantation.* 1990;5(4):241-246.

118. Hamazaki T, Tateno S, Shishido H. Eicosapentaenoic acid and IgA nephropathy. *Lancet*. 1984;1(8384): 1017-1018